Related Experiment Video
Updated: Feb 24, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder
Takeshi Terao1, Atsuko Ishida2,3, Toshifumi Kimura4
1Department of Neuropsychiatry, Oita University Faculty of Medicine, Oita, Japan.
Objective:
The preventive effects of mood stabilizers on recurrence/relapse in bipolar disorders have been investigated mostly in bipolar I disorder (BPI) patients, with limited reports on bipolar II disorder (BPII) patients. Here, we conducted an explorative data analysis to investigate whether the preventive effect of lamotrigine on recurrence /relapse in BPII is better than in BPI.
Methods:
Data from Japanese patients with a diagnosis of BPI or BPII according to DSM-IV-TR were analyzed in an open-label, noninterventional, naturalistic, prospective postmarketing surveillance study of lamotrigine. This study was carried out from October 2011 to November 2014, and each patient was observed for 1 year. The time to recurrence/relapse of mood episodes after commencement of lamotrigine treatment was evaluated as a primary endpoint. Kaplan-Meier curves were generated to compare the time to recurrence/relapse of mood episodes in BPI with in BPII using a log-rank test.
Results:
Lamotrigine was associated with a significantly longer time to recurrence/relapse of mood episodes in BPII than in BPI (log-rank test, P = .0103). Lamotrigine also prolonged time to recurrence/relapse of mania-related episodes, including hypomanic episodes, more in BPII than in BPI (P = .0110).
Conclusions:
Although the preventive effect of lamotrigine on recurrence/relapse of mood episodes in BPI has been established in a variety of clinical studies, the present study suggests that lamotrigine may be more suitable for maintenance treatment in BPII than in BPI.
More Related Videos
Related Concept Videos
Mania and Antimanic Drugs: Overview
Bipolar Disorder
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Psychosis: Goals of Pharmacotherapy
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Psychosis and Antipsychotic Drugs: Overview

